Literature DB >> 17398076

Continuous-infusion penicillin home-based therapy for serious infections due to penicillin-susceptible pathogens.

Aaron L Walton1, Benjamin P Howden, Lindsay M Grayson, Tony M Korman.   

Abstract

To evaluate the feasibility of continuous-infusion (CI) penicillin in the treatment of serious bacterial infections, consecutive adult patients with deep-seated infections due to penicillin-susceptible pathogens were treated with CI aqueous penicillin G in a home-based programme, and their treatment outcomes were reviewed. Thirty-one patients with microbiologically proven infections completed the planned course of treatment. Twenty of 31 (65%) were followed for at least 2 months thereafter, and all remained free of relapse. One patient had fever attributable to penicillin hypersensitivity, two patients developed catheter-site infections and one patient developed catheter-related bacteraemia. Thus, CI penicillin is feasible for the home-based treatment of a variety of deep-seated infections with minimal toxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17398076     DOI: 10.1016/j.ijantimicag.2006.10.018

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

1.  Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity.

Authors:  C Gardiol; R Voumard; C Cochet; S de Vallière
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-17       Impact factor: 3.267

2.  Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?

Authors:  Bruno Van Herendael; Axel Jeurissen; Paul M Tulkens; Erika Vlieghe; Walter Verbrugghe; Philippe G Jorens; Margareta Ieven
Journal:  Ann Intensive Care       Date:  2012-07-02       Impact factor: 6.925

Review 3.  Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review.

Authors:  E D Mitchell; C Czoski Murray; D Meads; J Minton; J Wright; M Twiddy
Journal:  BMJ Open       Date:  2017-04-20       Impact factor: 2.692

4.  Clinical Outcomes of Ceftriaxone vs Penicillin G for Complicated Viridans Group Streptococci Bacteremia.

Authors:  Stephanie Wo; Yanina Dubrovskaya; Justin Siegfried; John Papadopoulos; Shin-Pung Jen
Journal:  Open Forum Infect Dis       Date:  2020-11-07       Impact factor: 3.835

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.